Education
About Us
Working with TipRanks
Follow Us
Zomedica (ZOMDF)
OTHER OTC:ZOMDF
ZOMDF Stock Chart & Stats
$0.12
--
Market closed
$0.12
--
Day’s Range― - ―
52-Week Range$0.03 - $0.16
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.43M
Market Cap
$123.38M
Enterprise Value-$15.91M
Total Cash (Recent Filing)$76.88M
Total Debt (Recent Filing)$2.08M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding979,949,650
10 Day Avg. Volume1,820,838
30 Day Avg. Volume2,427,286
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.13
Enterprise Value/Revenue-0.60
Enterprise Value/Gross Profit-1.08
Enterprise Value/Ebitda0.29
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$45.33M
Bulls Say, Bears Say
Bulls Say
Financial PerformanceFinancial results show continued growth in an expanding market, meeting growth expectations both sequentially and in year-over-year comparisons.
Product InnovationZomedica has introduced several new assays for use with its TRUFORMA diagnostics platform, allowing veterinary practices to run tests without sending samples to an outside lab.
Sales GrowthThe TRUFORMA assays have been one of the sources of sales growth over the past year.
Bears Say
Price WeaknessAlthough Zomedica has made fundamental progress, the price weakness led to delisting and further price weakness.
Stock Price And DelistingThe closing price of Zomedica stock fell below $0.10 per share, forcing the delisting of ZOM shares.
Zomedica News
ZOMDF FAQ
What was Zomedica’s price range in the past 12 months?
Zomedica lowest stock price was $0.03 and its highest was $0.16 in the past 12 months.
What is Zomedica’s market cap?
Zomedica’s market cap is $123.38M.
When is Zomedica’s upcoming earnings report date?
Zomedica’s upcoming earnings report date is May 07, 2026 which is in 60 days.
How were Zomedica’s earnings last quarter?
Currently, no data Available
Is Zomedica overvalued?
According to Wall Street analysts Zomedica’s price is currently Overvalued.
Does Zomedica pay dividends?
Zomedica does not currently pay dividends.
What is Zomedica’s EPS estimate?
Zomedica’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zomedica have?
Zomedica has 979,949,650 shares outstanding.
What happened to Zomedica’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Zomedica?
Currently, no hedge funds are holding shares in ZOMDF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zomedica Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.1%
Last 30 Days ▲ 6.0%
Last 30 Days ▲ 6.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-43.90%
12-Months-Change
Fundamentals
Return on Equity
-50.95%
Trailing 12-Months
Asset Growth
-37.93%
Trailing 12-Months
Company Description
Zomedica
Zomedica Pharmaceuticals Corp. operates as a development stage veterinary diagnostic and pharmaceutical company. It creates products for companion animals by focusing on the unmet needs of clinical veterinarians. The company was founded by Gerald L. Solensky, Jr. on January 7, 2013 and is headquartered in Ann Arbor, MI.
ZOMDF Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Zomedica's earnings call highlighted strong revenue growth, especially in the diagnostics segment, and successful international expansion. However, these positives were countered by significant challenges, including the delisting from the NYSE and an increased net loss. The company's strong liquidity position and product innovation are promising, but these are tempered by market and operational challenges.View all ZOMDF earnings summariesTechnical Analysis
aTyr Pharma
―
vTv Therapeutics
―
Relmada Therapeutics
―
PMV Pharmaceuticals
―
Pulmonx
―
Ownership Overview
2.63% Insiders
0.03% Mutual Funds
0.07% Other Institutional Investors
97.27% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---